^
Association details:
| Biomarker: | CAPRIN-1 expression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) + TRK-950 (Caprin-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.
Published date:
01/17/2023
Excerpt:
Four patients had a screening CAPRIN-1 score of 3+, and all achieved partial response….TRK-950 binds to a newly described target, CAPRIN-1, and has an acceptable safety and tolerability profile when combined with ramucirumab and paclitaxel in gastric cancer including GEJ cancer. Preliminary clinical activity is demonstrated in pre-treated patients with encouraging response rates, particularly enriched by the expression of CAPRIN-1.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2023.41.3_suppl.361
Trial ID:
